New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data

Gainers Plus Therapeutics (NASDAQ:PSTV) shares rose 20.3% to $1.48 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 1.0 million shares, which is 236.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.2 million. The company's, Q3 earnings came out today. NewAmsterdam Pharma (NASDAQ:NAMS) shares increased by 11.11% to $10.0. The company's market cap stands at $823.2 million. China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 10.23% to $2.37. The company's market cap stands at $1.3 million. DarioHealth (NASDAQ:DRIO) stock moved upwards by 7.81% to $1.38. The market value of

Gainers Soleno Therapeutics (NASDAQ:SLNO) shares increased by 426.2% to $23.31 during Tuesday's regular session. Soleno Therapeutics's stock is trading at a volume of 32.5 million shares as of 13:30 EST. This is 51215.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $232.9 million. Femasys (NASDAQ:FEMY) shares rose 272.43% to $1.24. As of 13:30 EST, Femasys's stock is trading at a volume of 147.8 million, which is 3882.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $18.6 million. DMK Pharmaceuticals (NASDAQ:DMK) stock rose 160.42% to $1.18. Trading volume for this secu

Gainers Soleno Therapeutics (NASDAQ:SLNO) shares increased by 386.4% to $21.55 during Tuesday's pre-market session. The company's market cap stands at $215.3 million. Femasys (NASDAQ:FEMY) shares increased by 243.78% to $1.14. The market value of their outstanding shares is at $17.1 million. Intercept Pharma (NASDAQ:ICPT) shares increased by 78.44% to $18.63. The market value of their outstanding shares is at $778.4 million. Immunovant (NASDAQ:IMVT) stock increased by 60.05% to $32.46. The market value of their outstanding shares is at $4.2 billion. Tharimmune (NASDAQ:THAR) stock increased by 54.24% to $0.34. The market value of their outstanding shares is at $5.9 million. Sharps Techn

Gainers TransCode Therapeutics (NASDAQ:RNAZ) shares rose 219.3% to $2.12 during Monday's regular session. TransCode Therapeutics's stock is trading at a volume of 72.3 million shares as of 13:30 EST. This is 12088.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.2 million. Vaccitech (NASDAQ:VACC) shares increased by 82.73% to $3.07. Trading volume for Vaccitech's stock is 18.2 million as of 13:30 EST. This is 135511.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $118.2 million. Biophytis (NASDAQ:BPTS) shares moved upwards by 71.57% to $1.51. As of 13:30 EST, this se

Upgrades For Steel Dynamics Inc (NASDAQ:STLD), Citigroup upgraded the previous rating of Neutral to Buy. For the second quarter, Steel Dynamics had an EPS of $4.81, compared to year-ago quarter EPS of $6.73. The current stock performance of Steel Dynamics shows a 52-week-high of $136.46 and a 52-week-low of $69.12. Moreover, at the end of the last trading period, the closing price was at $101.10. Citigroup upgraded the previous rating for Cleveland-Cliffs Inc (NYSE:CLF) from Neutral to Buy. For the second quarter, Cleveland-Cliffs had an EPS of $0.69, compared to year-ago quarter EPS of $1.31. The stock has a 52-week-high of $22.83 and a 52-week-low of $11.82. At the end of the last tradi

Alliance Global Partners analyst James Molloy initiates coverage on Vaccitech (NASDAQ:VACC) with a Buy rating and announces Price Target of $12.

New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, November 10-14 in Boston, MA. The company also announced today that it has changed its name to Barinthus Biotherapeu

OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and potential paths to a functional cure. Details are as follows: KOL Webinar: Seeking a Functional Cure for Chronic Hepatis BWednesday, September 20, 2023 between 14:00-15:00 ET.To register for the event

OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress. "In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL," said Bill Enright, Vaccitech's Ch

Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitorTwo patients developed a non-detectable HBsAg level, which continued eight months after last doseA robust T cell response was generated and was highest in participants who received VTP-300 aloneVTP-300 led to a decline in HBsAg in adults with chronic Hepatitis B with either genotype B or C viruses. VTP-300-elicited T cells have shown cross-reactivity to HBV core antigen from genotypes A to E in vitro OXFORD, United Kingdom, June 21, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in

Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a triple combination clinical trial that has been expanded to include a PD-1 monoclonal antibody, nivolumab. Nivolumab is approved for a number of types of cancer under the brand name, Opdivo®. The obje

OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer, today announced the dosing of the first patient in the PCA001 clinical trial (NCT05617040). PCA001 is a multi-centre, Phase 1/2 clinical trial designed to determine the recommended Phase 2 regimen and evaluate the safety, efficacy, as measured by prostate-specific antigen (PSA) response, and T cell response of VTP-850 monotherapy in men with rising PSA after definitive local therapy for their dise

OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company's progress. "2023 has kicked off strongly for Vaccitech. In the first quarter, we strengthened our leadership team with the addition of Dr. Nadège Pelletier as our new Chief Scientific Officer, we generated positive final proof of concept data from one of o

VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events (SAEs) in women with low grade human papillomavirus-related cervical lesionsInterim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6 antigens OXFORD, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat and cure chronic infectious diseases, autoimmune diseases and cancer, will present to

Building capacity in Gene Therapy Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) ("Pharmaron") announced today that their Liverpool, UK based Gene Therapy CDMO has received a prestigious grant from the UK Government's Life Sciences Innovation Manufacturing Fund (LSMIF) to expand their viral vector and DNA manufacturing facilities for more than 8,000 sqM. This major expansion project will provide a four-fold increase in gene therapy process development and analytical capacity accommodating viral vector, DNA and RNA drug substance, plus drug product formulation. The expansion includes 3,500 sqM for future commercial scale GMP capacity. The resulting facility will greatly en

Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen (HBsAg)Results will be presented at the upcoming European Association for the Study of the Liver (EASL) Congress in June OXFORD, United Kingdom, March 28, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics designed to use the power of the immune system to potentially treat and cure chronic infectious diseases, autoimmune diseases and cancer, today announced positive topline final data fro